Volume 28, Number 7—July 2022
Research
Targeted Screening for Chronic Q Fever, the Netherlands
Table 2
GP practice† | Province | No. eligible patients‡ | Study participants, no. (%) | Seroprevalence (IgG II titer >1:64), no. (%) | No. suspected of having chronic Q fever (IgG I titer >1:512) |
---|---|---|---|---|---|
1 | NB | 358 | 216 (60) | 51 (24) | 0 |
2 | NB | 250 | 108 (43) | 18 (17) | 0 |
3 | NB | 477 | 255 (53) | 58 (23) | 2 |
4 | NB | 267 | 160 (60) | 48 (30) | 2 |
5 | NB | 144 | 84 (58) | 21 (25) | 1 |
6 | NB | 381 | 183 (48) | 22 (12) | 1 |
7 | NB | 108 | 58 (54) | 9 (16) | 0 |
8 | FR | 124 | 40 (32) | 11 (28) | 0 |
9 | LI | 308 | 143 (46) | 28 (20) | 2 |
10 | LI | 376 | 147 (46) | 4 (3) | 0 |
11 | LI | 239 | 110 (46) | 9 (8) | 0 |
12 | LI | 134 | 53 (40) | 2 (4) | 1 |
13 | UT | 253 | 85 (34) | 8 (9) | 0 |
Total | NA | 3,419 | 1,642 (48) | 289 (18) | 9 |
*GP, general practitioner; FR, Friesland; LI, Limburg; NA, not applicable; NB, North-Brabant; UT, Utrecht. †Corresponding to numbers in [[ANCHOR###F1###Figure 1###Anchor]]. ‡Eligible patients are patients who had increased risk for development of chronic Q fever after infection with Coxiella burnetii (see [[ANCHOR###T1###Table 1###Anchor]] for specified inclusion criteria).
Page created: May 06, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.